Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments
October 06, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network
September 23, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
September 20, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal
August 09, 2022 08:00 ET
|
Alimera Sciences, Inc.
Reimbursement granted with no restrictions to the labelAlimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global...
Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients
July 26, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, July 26, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France
July 22, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress
July 13, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, July 13, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
July 08, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes
May 12, 2022 08:03 ET
|
Alimera Sciences, Inc.
ATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Reports First Quarter 2022 Results
May 09, 2022 08:00 ET
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021U.S. Net Revenue Increased 23% vs. First Quarter of 2021U.S. End User Demand Up 25% vs. First Quarter of 2021 ATLANTA, May ...